2026-04-18T03:31:39Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/189172024-09-27T07:56:06Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Santamans, Ayelén M author Cicuéndez, Beatriz author Mora, Alfonso author Villalba-Orero, María author Rajlic, Sanela author Crespo, María author Vo, Paula author Jerome, Madison author Macías, Álvaro author López, Juan Antonio author Leiva, Magdalena author Rocha, Susana F author León, Marta author Rodríguez, Elena author Leiva, Luis author Pintor Chocano, Aránzazu author García Lunar, Inés author García-Álvarez, Ana author Hernansanz-Agustín, Pablo author Peinado, Víctor I author Barberá, Joan Albert author Ibáñez, Borja author Vázquez, Jesús author Spinelli, Jessica B author Daiber, Andreas author Oliver, Eduardo author Sabio, Guadalupe author 2024-01-19 Pulmonary hypertension (PH) can affect both pulmonary arterial tree and cardiac function, often leading to right heart failure and death. Despite the urgency, the lack of understanding has limited the development of effective cardiac therapeutic strategies. Our research reveals that MCJ modulates mitochondrial response to chronic hypoxia. MCJ levels elevate under hypoxic conditions, as in lungs of patients affected by COPD, mice exposed to hypoxia, and myocardium from pigs subjected to right ventricular (RV) overload. The absence of MCJ preserves RV function, safeguarding against both cardiac and lung remodeling induced by chronic hypoxia. Cardiac-specific silencing is enough to protect against cardiac dysfunction despite the adverse pulmonary remodeling. Mechanistically, the absence of MCJ triggers a protective preconditioning state mediated by the ROS/mTOR/HIF-1α axis. As a result, it preserves RV systolic function following hypoxia exposure. These discoveries provide a potential avenue to alleviate chronic hypoxia-induced PH, highlighting MCJ as a promising target against this condition. Sci Adv. 2024 Jan 19;10(3):eadk6524. http://hdl.handle.net/20.500.12105/18917 38241373 10.1126/sciadv.adk6524 2375-2548 Science advances MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension.